Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...
Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study The College of American ...
Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s IMFINZI® ...
Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of 20 ...
Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...
Mistakes in mismatch repair genes, which occur in sporadic and hereditary forms of colorectal, endometrial, stomach, biliary tract, pancreas, ovarian and small intestine cancer, disable cells' ability ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results